Anti-cancer drug identified by UCLA researchers shows promise treating high-risk COVID-19 patients
UCLA Health Connect blog
Researchers from UCLA are part of a collaboration of scientists from several universities studying the potential that the anti-cancer drug berzosertib could be effective in treating or preventing SARS-CoV-2, the virus that causes COVID-19.
In development by the German drug manufacturer Merck KGaA Darmstadt, Germany, berzosertib is a protein kinase inhibitor that has shown to be effective in treating small-cell lung cancer, ovarian cancer and other types of cancers by blocking the tumor’s ability to replicate. Protein kinase inhibitors are substances that block the action of enzymes responsible for cell signaling, growth and division, among other functions.
Berzosertib is currently in separate early- and mid-stage clinical trials in combination with chemotherapy.
Click here to read the UCLA Health Connect blog.